Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1319.

https://doi.org/10.1182/blood-2019-131394

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients

Quande Lin, PhD, Lu Han, MS, Jian Zhou, MD PhD, Lina Liu, Master, Yuzhang Liu, master, Fengkuan Yu, Master, YangLi Zhang, Master, Wenli Zuo, Doctor, Keshu Zhou, MD, Baijun Fang, MD, Quanli Gao, Doctor, Xudong Wei, PhD, Delong Liu, MD PhD, Yongping Song, MD PhD

Blood (2019) 134 (Supplement_1): 1851.

https://doi.org/10.1182/blood-2019-128410

Published: 2019

Journal Articles

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Blood (2019) 134 (Supplement_1): 1656.

https://doi.org/10.1182/blood-2019-130691

Published: 2019

Journal Articles

Diplotype Analysis of NUDT15 Variants By Targeted Sequencing in Pediatric Acute Lymphoblastic Leukemia

Chih-Hsiang Yu, Ya-Hsuan Chang, PhD, Wen-Chien Chou, MD, PhD, Der-Shiun Wang, MD, Shu-Wha Lin, PhD, Hsuan-Yu Chen, PhD, Yung-Li Yang, MD PhD

Blood (2019) 134 (Supplement_1): 1305.

https://doi.org/10.1182/blood-2019-124053

Published: 2019

Journal Articles

Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia

Amany R. Keruakous, MD, Jennifer Holter Chakrabarty, MD, Sarah Ann Schmidt, PharmD, Mohamad O. Khawandanah, MBBS, George Selby, MD, Carrie Yuen, MD

Blood (2019) 134 (Supplement_1): 3297.

https://doi.org/10.1182/blood-2019-128316

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle Cell Anemia

Alex George, MD PhD, Bogdan Dinu, MD, Norma Estrada, Charles Minard, PhD, Richard L Hurwitz, MD, Donald Mahoney, MD, Amber M Yates, MD, Mary Vaughan, FNP - C, Alaundra Carmouche, FNP - C, Gladstone Airewele, MDMPH, Kirk E Susan, P.A., Titilope Adenike Fasipe, MD PhD, Precious Uwaezuoke, FNP, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 2267.

https://doi.org/10.1182/blood-2019-127414

Published: 2019

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Blood (2019) 134 (Supplement_1): 2838.

https://doi.org/10.1182/blood-2019-126481

Published: 2019

Journal Articles

Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy

Ramnath K Shenoy, MD, Anant Gokarn, MD, Anup Toshniwal, MDDM, Siddhesh Arun Kalantri, MD, Akanksha Chichra, DNB, Sachin Punatar, MBBS,MDDM MDcal Oncology, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Libin J Mathew, Vivek Bhat, MD, Sanjay Biswas, MD, Rohini Kelkar, MD, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4506.

https://doi.org/10.1182/blood-2019-128766

Published: 2019

Journal Articles

Predicting Minimal Residual Disease in Acute Myeloid Leukemia through Stochastic Modeling of Clonality

Khanh Dinh, Roman Jaksik, PhD, Marek Kimmel, PhD DSc, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 1448.

https://doi.org/10.1182/blood-2019-127457

Published: 2019

Journal Articles

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Michaela Liedtke, MD, Margaret R O'Donnell, MD, Ibrahim Aldoss, MD, Martha P. Mims, MD PhD, Kristen Marie O'Dwyer, MD, Megan Othus, PhD, Harry P. Erba, MD PhD

Blood (2019) 134 (Supplement_1): 227.

https://doi.org/10.1182/blood-2019-125340

Published: 2019

Journal Articles

Maximum 24-Hour Platelet Count Fall Rate As a Predictor of HIT

Daniel S Lefler, MD, Adam Cuker, MD MS, Allyson M Pishko, MD

Blood (2019) 134 (Supplement_1): 1072.

https://doi.org/10.1182/blood-2019-131173

Published: 2019

Journal Articles

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Blood (2019) 134 (Supplement_1): 677.

https://doi.org/10.1182/blood-2019-125579

Published: 2019

Journal Articles

Combination of Venetoclax and Hypomethylating Agents in Myeloid Malignancies in Patients Unfit for Intensive Chemotherapy - Real World Data from a Tertiary Care Centre in India. Is It Time to Bid Adieu to 3+7?

Sumeet Prakash Mirgh, MBBS, MDDM, Jyotsna Kapoor, MSc, Shinto Francis Thekuddan, MD DM, Vishvdeep Khushoo, MBBS, MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5149.

https://doi.org/10.1182/blood-2019-131746

Published: 2019

Journal Articles

Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study

Nicola Conran, PhD, Kleber Yotsumoto Fertrin, MD PhD, Claudia de Alvarenga Maximo, MD, Thais Oliveira, B.Sc., Clarisse Lobo, MD PhD, Fernando Ferreira Costa, MD PhD

Blood (2019) 134 (Supplement_1): 2303.

https://doi.org/10.1182/blood-2019-130106

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Heather M Schroeder, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Monica Kwari, BSN, Christopher Loiselle, BS, Rebecca Garris, MSc, Nicole Volter, RDC, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Koichi Takahashi, MD, Koji Sasaki, MD, William G. Wierda, MD PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3807.

https://doi.org/10.1182/blood-2019-129657

Published: 2019

Journal Articles

Voice of Cancer Patients: Patient Experience Regarding Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Sangeeta Aggarwal, MD, Singh Manish, B.Tech, Guroosh Chaudhary, Alok Aggarwal, PhD, Himanshu Punetha, M. Tech, Juhi Jha, Rahul Kumar Gond

Blood (2019) 134 (Supplement_1): 5843.

https://doi.org/10.1182/blood-2019-125195

Published: 2019

NARROW

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Diplotype Analysis of NUDT15 Variants By Targeted Sequencing in Pediatric Acute Lymphoblastic Leukemia

Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle Cell Anemia

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy

Predicting Minimal Residual Disease in Acute Myeloid Leukemia through Stochastic Modeling of Clonality

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Maximum 24-Hour Platelet Count Fall Rate As a Predictor of HIT

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Combination of Venetoclax and Hypomethylating Agents in Myeloid Malignancies in Patients Unfit for Intensive Chemotherapy - Real World Data from a Tertiary Care Centre in India. Is It Time to Bid Adieu to 3+7?

Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Voice of Cancer Patients: Patient Experience Regarding Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only